Category | Number of trials | % |
---|---|---|
1. Malignancy/others | Â | Â |
Malignancy | 1,327 | 47.8 |
Others | 1,452 | 52.2 |
2. Genomic information | Â | Â |
Used | 230 | 8.3 |
Not used | 2,549 | 91.7 |
3. Confirmatory/exploratory | Â | Â |
Confirmatory | 1,010 | 36.3 |
Exploratory | 762 | 27.4 |
Missing data | 1,007 | 36.2 |
4. Explanatory/pragmatic | Â | Â |
Explanatory | 326 | 11.7 |
Pragmatic | 1,081 | 38.9 |
Missing data | 1,372 | 49.4 |
5. Basic design | Â | Â |
Parallel | 1,334 | 48.0 |
Crossover | 135 | 4.9 |
Factorial | 17 | 0.6 |
Single-arm | 1,289 | 46.4 |
Expanded access | 4 | 0.1 |
6. Randomization | Â | Â |
Randomized | 1,346 | 48.4 |
Non-randomized | 1,433 | 51.6 |
7. Blinding | Â | Â |
Open | 2,181 | 78.5 |
Assessor blinded | 298 | 10.7 |
Single-blind (participants) | 87 | 3.1 |
Single-blind (investigators and assessors) | 33 | 1.2 |
Double-blind | 180 | 6.5 |
8. Control | Â | Â |
Placebo | 187 | 6.7 |
No treatment | 249 | 9.0 |
Active | 959 | 34.5 |
Dose comparison | 70 | 2.5 |
Historical | 281 | 10.1 |
Uncontrolled | 1,033 | 37.2 |
9. Number of arms | Â | Â |
1 | 1,289 | 46.4 |
2 | 1,282 | 46.1 |
3 | 145 | 5.2 |
>4 | 63 | 2.3 |
10. Type of intervention a | Â | Â |
Medicine | 2,074 | 74.6 |
Vaccine | 112 | 4.0 |
Genetic | 16 | 0.6 |
Food | 75 | 2.7 |
Device, equipment | 273 | 9.8 |
Behavior, custom | 133 | 4.8 |
Maneuver | 445 | 16.0 |
Others | 0 | 0.0 |
11. Target sample size | Â | Â |
1 to 10 | 210 | 7.6 |
11 to 100 | 1,781 | 64.1 |
101 to 1,000 | 725 | 26.1 |
1001 to 1,0000 | 58 | 2.1 |
>10,000 | 5 | 0.2 |
12. Trial period (months)b | Â | Â |
0 to 6 | 138 | 5.0 |
7 to 12 | 180 | 6.5 |
13 to 36 | 1,057 | 38.0 |
37 to 60 | 611 | 22.0 |
>60 | 428 | 15.4 |
Missing data | 365 | 13.1 |
13. Report of results c | Â | Â |
Unpublished | 2,501 | 90.0 |
Published | 136 | 4.9 |
Partially published | 142 | 5.1 |
14. Disclosure of trial before/after trial start d | Â | Â |
Disclosure first | 303 | 10.9 |
Trial start first | 2,476 | 89.1 |
Total | 2,779 | 100 |